15.78

4.88% -0.81

Aurinia Pharmaceuticals Inc (AUPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AUPH? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$16.59

Offen:

$16.49

24-Stunden-Volumen:

1.20M

Relative Volume:

0.84

Marktkapitalisierung:

$2.03B

Einnahmen:

$298.30M

Nettoeinkommen (Verlust:

$298.21M

KGV:

7.2931

EPS:

2.1637

Netto-Cashflow:

$166.93M

1W Leistung:

+1.09%

1M Leistung:

+0.77%

6M Leistung:

+4.16%

1J Leistung:

+76.71%

1-Tages-Spanne:

$15.48

$16.54

1-Wochen-Bereich:

$15.37

$16.70

52-Wochen-Spanne:

$8.55

$19.25

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Firmenname

Aurinia Pharmaceuticals Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

250-744-2487

Adresse

#140, 14315 - 118 AVENUE, EDMONTON, BC

Mitarbeiter

128

Twitter

@AuriniaPharma

Nächster Verdiensttermin

2026-07-30

Neueste SEC-Einreichungen

AUPH's Discussions on Twitter

Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AUPH Aurinia Pharmaceuticals Inc	15.78	2.03B	298.30M	298.21M	166.93M	2.1637
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-03	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-11-07	Hochstufung	Jefferies	Hold → Buy
2025-11-05	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-07-30	Fortgesetzt	H.C. Wainwright	Buy
2022-11-04	Herabstufung	Oppenheimer	Outperform → Perform
2022-05-05	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-12-10	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2021-01-25	Bestätigt	H.C. Wainwright	Buy
2020-11-03	Bestätigt	H.C. Wainwright	Buy
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-05-05	Eingeleitet	Cowen	Outperform
2020-01-10	Eingeleitet	Jefferies	Buy
2019-12-16	Bestätigt	H.C. Wainwright	Buy
2018-03-16	Bestätigt	Cantor Fitzgerald	Overweight
2018-02-08	Eingeleitet	RBC Capital Mkts	Outperform
2017-10-30	Bestätigt	H.C. Wainwright	Buy
2017-05-18	Bestätigt	H.C. Wainwright	Buy
2017-04-11	Eingeleitet	Cantor Fitzgerald	Overweight
2017-03-22	Bestätigt	FBR & Co.	Outperform
2016-12-30	Bestätigt	H.C. Wainwright	Buy
2016-08-17	Bestätigt	H.C. Wainwright	Buy
2016-06-30	Eingeleitet	H.C. Wainwright	Buy
2015-05-08	Eingeleitet	MLV & Co	Buy

Alle ansehen

Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten

Jul 11, 2026

Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily

Jul 11, 2026

Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy? - Sahm

Jul 11, 2026

Jul 09, 2026

Price to earnings forward of Aurinia Pharmaceuticals Inc. – MUN:IKAP - TradingView

Jul 09, 2026

Jul 07, 2026

AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView

Jul 07, 2026

Jul 06, 2026

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace

Jul 06, 2026

TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Jul 06, 2026

Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments - Investing.com

Jul 06, 2026

Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa

Jul 06, 2026

Jul 05, 2026

Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - ad-hoc-news.de

Jul 05, 2026

Jul 04, 2026

Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView

Jul 04, 2026

Jul 03, 2026

If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo

Jul 01, 2026

Jun 30, 2026

Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jun 30, 2026

Jun 29, 2026

Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey

Jun 29, 2026

Jun 27, 2026

IKAP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026